Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME) that may inhibit the antitumor T cell activity. We found that pharmacological inhibition of the acid loader chloride/bicarbonate anion exchanger 2 (Ae2), with 4,4’-diisothi...

Descripción completa

Detalles Bibliográficos
Autores: Navarro-Negredo, F.C. (Flor Cecilia)|||/items/e4384704-3a73-45b3-b5fd-f7a2142bd783, Casares-Lagar, N. (Noelia)|||/items/32524a9b-f393-47ee-bf77-0737c65e0b7b, Martín-Otal, C. (Celia)|||/items/083c0c6b-72c5-42ae-a734-97702ba72711, Lasarte-Cia, A. (Aritz)|||/items/a2c6eec9-7b5d-49da-86d3-dfee52b636cf, Gorraiz, M. (Marta)|||/items/2f64930e-4c40-41d8-9a41-8a29266a623f, Sarrión, P. (Patricia)|||/items/620eae1c-0788-4b5f-8a1e-3250d1cb13a9, Llopiz-Khatchikian, D.I. (Diana Isabel)|||/items/3b1cd705-ce8b-4f99-b323-460f59b34f20, Repáraz-Pernaut, D. (David)|||/items/c0618bbc-c5af-4ee0-8660-0de8471413e8, Varo-Cenarruzabeitia, N. (Nerea)|||/items/18b5a757-44b9-4e23-8a8c-ad907969001f, Rodriguez-Madoz, J.R. (Juan Roberto)|||/items/9c21019b-aeba-4cdc-b78e-178a176da535, Prosper-Cardoso, F. (Felipe)|||/items/3d1b0b82-06c3-4e63-8280-e903dc4dc0c1, Lozano-Moreda, T. (Teresa)|||/items/f7df715d-1380-479b-8134-b319df8f0b00, Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0c, Hervas-Stubbs, S. (Sandra)|||/items/8f56cb52-4465-4428-8acf-e50439c6be8f
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/112506
Acceso en línea:https://hdl.handle.net/10171/112506
Access Level:acceso abierto
Palabra clave:Lymphocytes
intracellular pH
tumor microenvironment
AE2
HVCN1
adoptive cell therapy
Descripción
Sumario:The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME) that may inhibit the antitumor T cell activity. We found that pharmacological inhibition of the acid loader chloride/bicarbonate anion exchanger 2 (Ae2), with 4,4’-diisothiocyanatostilbene-2,2’-disulfonicacid (DIDS) enhancedCD4+ andCD8+ T cell function upon TCR activation in vitro, especially under low pH conditions. In vivo, DIDS administration delayed B16OVA tumor growth in immunocompetent mice as monotherapy or when combined with adoptive T cell transfer of OVA-specificT cells. Notably, genetic Ae2 silencing in OVA-specificT cells improvedCD4+/CD8+ T cell function in vitro as well as their antitumor activity in vivo. Similarly, genetic modification of OVA-specificT cells to overexpress Hvcn1, a selectiveH+ outward current mediator that prevents cell acidification, significantly improved T cell function in vitro, even at low pH conditions. The adoptive transfer of OVA-specificT cells overexpressing Hvcn1 exerted a better antitumor activity in B16OVA tumor-bearingmice. Hvcn1 overexpression also improved the antitumor activity of CAR T cells specific for Glypican 3 (GPC3) in mice bearing PM299L-GPC3tumors. Our results suggest that preventing intracellular acidification by regulating the expression of acidifier ion channels such as Ae2 or alkalinizer channels like Hvcn1 in tumor-specificlymphocytes enhances their antitumor response by making them more resistant to the acidic TME.